On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...